Unlock instant, AI-driven research and patent intelligence for your innovation.

Methods of treatment using a jak inhibitor compound

A composition and drug technology, applied in the direction of medical preparations containing active ingredients, drug combination, drug delivery, etc., can solve the problems of undisclosed compound 1

Active Publication Date: 2019-12-13
THERAVANCE BIOPHARMA R&D IP LLC
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the present application does not disclose the use of compound 1 for the treatment of eye diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treatment using a jak inhibitor compound
  • Methods of treatment using a jak inhibitor compound
  • Methods of treatment using a jak inhibitor compound

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0188] Example 1: 5-Ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4 ,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol crystalline hydrate

[0189]

[0190]To a 3 L flask was added NMP (239 mL) and 5-ethyl-2-fluoro-4-(3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c] Pyridin-2-yl)-lH-indazol-6-yl)phenol 2HCl (74.5 g, 165 mmol) followed by addition of NMP (74 mL). Acetic acid (31.3 mL) was added and the reaction mixture was warmed to 55 °C for 10 min and then cooled to 25 °C. 1-Methylpiperidin-4-one (61.0 mL, 496 mmol) was added in one portion and the reaction mixture was stirred at 25 °C for 30 min and cooled to 15 °C. Sodium triacetoxyborohydride (98 g, 463 mmol) was added and after 5 min the external jacket was set to 20°C. After 3 h, ammonium hydroxide (365 mL, 5790 mmol) was added dropwise over 45 min, maintaining the temperature below 25 °C. The reaction mixture was stirred at 20 °C for 1.5 h, resulting in the formation of an off-white slurry. Methano...

example 2

[0192] Example 2: Powder X-ray Diffraction

[0193] with a Bruker D8-Advance X-ray diffractometer, using Cu-Kα radiation The powder X-ray diffraction (PXRD) pattern of the product of Example 1 was obtained at an output voltage of 45 kV and a current of 40 mA. The instrument was operated in Bragg-Brentano geometry, where the incidence, divergence and scattering slits were set to maximize the intensity at the sample. For measurements, a small amount of powder (5-25 mg) was gently pressed onto the sample holder to form a smooth surface, and subjected to X-ray exposure. The sample was scanned in 2Θ from 2° to 40° in 2Θ-2Θ mode with a step size of 0.02° and a scanning speed of 0.30° sec per step. Data acquisition was controlled by Bruker DiffracSuite measurement software and analyzed by Jade software (version 7.5.1). The instrument was calibrated within ±0.02° 2Θ with corundum standards. The observed PXRD 2Θ peak positions and d-spacings are shown in Table 1.

[0194] Table 1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
Login to View More

Abstract

The invention relates to methods of treating ocular diseases and certain respiratory diseases using the compound 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol Formula or a pharmaceutically-acceptable salt thereof.

Description

technical field [0001] The present invention relates to methods of treating ocular diseases and certain respiratory diseases using specific JAK inhibitor compounds or pharmaceutically acceptable salts thereof. Background technique [0002] Cytokines are intercellular signaling molecules that include chemokines, interferons, interleukins, lymphoid mediators, and tumor necrosis factor. Cytokines are critical for normal cell growth and immune regulation, and also drive immune-mediated diseases and contribute to malignant cell growth. Higher levels of many cytokines have been implicated in a number of diseases or conditions, specifically those diseased lesions characterized by inflammation. Multiple cytokines involved in disease function throughout signaling pathways relying on the Janus family of tyrosine kinases (JAKs), which act through signal transducers of transcription factors and activation of transcription Factor (STAT) family to transmit signals. [0003] The JAK fam...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4545A61K9/00A61P27/02A61P11/00
CPCA61K9/0075A61K9/0078A61K31/4545A61P27/02A61K9/0048A61P11/00A61K9/0019A61K9/008
Inventor V·R·萨兰迪张浩M·A·克莱因舍尔克G·D·克拉泰尔
Owner THERAVANCE BIOPHARMA R&D IP LLC